613-84-3

Basic information

• Product Name: 5-Methylsalicylaldehyde
• Synonyms: 2-hydroxy-5-methyl-benzaldehyd;ASISCHEM D29246;2,5-CRESOTALDEHYDE;2-HYDROXY-5-METHYLBENZALDEHYDE;2-HYDROXY-5-METHYLSALICYLALDEHYDE;5-METHYLSALICYLALDEHYDE;2-Hydroxy-5-Methylbenzaldehyde (5-Methoxysalicylaldehyde);Benzaldehyde, 2-hydroxy-5-methyl-
• CAS NO: 613-84-3
• Molecular Formula: C₈H₈O₂
• Molecular Weight: 136.15
• EINECS: 210-357-6
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aldehydes;Building Blocks;C8;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 613-84-3.mol
• Article Data: 75

Chemical Properties

• Melting Point: 54-57 °C(lit.)
• Boiling Point: 217 °C(lit.)
• Flash Point: 85.1 °C
• Appearance: Pale yellow to yellow/Crystalline Powder
• Density: 1.0913
• Vapor Pressure: 0.09mmHg at 25°C
• Refractive Index: 1.5470 (estimate)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 8.47±0.18(Predicted)
• BRN: 2040673
• CAS DataBase Reference: 5-Methylsalicylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methylsalicylaldehyde(613-84-3)
• EPA Substance Registry System: 5-Methylsalicylaldehyde(613-84-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 613-84-3(Hazardous Substances Data)

Usage

Uses

2-Hydroxy-5-methylbenzaldehyde is used in preparation of novel 2-Phenylcyclopropanamine derivatives as Lysine-specific Demethylase 1 inhibitors (LSD1-inhibitors) for prevention or treatment of primary brain tumor.

InChI:InChI=1/C8H8O2/c1-6-2-3-8(10)7(4-6)5-9/h2-5,10H,1H3

Upstream product

• 50-00-0 formaldehyd 
• 106-44-5 p-cresol 
• 302-17-0 chloral hydrate 
• 74-90-8 hydrogen cyanide 
• 67-66-3 chloroform 
• 22068-59-3 2-(1,3-dithiolan-2-yl)-p-cresol 
• 13460-50-9 metaboric acid 
• 56-81-5 glycerol 
• 110-54-3 hexane 
• 109-88-6 magnesium methanolate 
• 68-12-2 N,N-dimethyl-formamide 
• 55359-68-7 2-(methoxymethoxy)-5-methylbenzaldehyde 
• 89-56-5 5-Methylsalicylic acid 
• 4383-07-7 2-hydroxymethyl-4-methylphenol 

Downstream Products

• 10242-13-4 6-methyl-2-oxo-2H-chromene-3-carboxylic acid 
• 77117-15-8 6-methyl-3-acetyl coumarin 
• 327613-95-6 3-benzoyl-6-methyl-2H-chromen-2-one 
• 19430-16-1 5-methyl-salicylidene-p-methylaniline 
• 110252-72-7 4-methyl-2-(6-methyl-[2]quinolyl)-phenol 
• 53389-98-3 2-(benzyloxy)-5-methylsalicylaldehyde 
• 88521-64-6 2-formyl-4-methylphenoxyacetic acid 
• 88521-73-7 ethyl 2-(2-formyl-4-methylphenoxy)acetate 
• 10242-09-8 5-methylbenzofuran-2-carboxylic acid 
• 20772-62-7 4-(2-hydroxy-5-methyl-benzylidenamino)-benzoic acid ethyl ester 
• 106038-85-1 2-[(4-bromo-phenylimino)-methyl]-4-methyl-phenol 
• 59129-92-9 2-[2-aza-2-(5-methyl-(2-pyridyl))vinyl]phenol 

Relevant articles and documents

-

-

Phosphine-catalyzed sequential (2+3)/(2+4) annulation of γ-vinyl allenoates: Access to the synthesis of chromeno[4,3-: B] pyrroles

A phosphine-catalyzed cascade (2+3)/(2+4) cyclization reaction of γ-vinyl allenoates with aldimine esters has been developed to provide a series of chromeno[4,3-b]pyrrole derivatives that contain three contiguous stereogenic centers. The method gives a good yield, excellent chemoselectivity and diastereoselectivity under mild conditions.

In Vitro Antitumor Activity of Newly Synthesized Pyridazin-3(2H)-One Derivatives via Apoptosis Induction

Systemic toxicity associated with drug resistance continues to be the major obstacle to curative therapy of cancer. Tumor cell resistance to chemotherapeutic drugs often results in coordinate resistance to other structurally and functionally unrelated drugs and the subsequent development of cross resistance phenotype. Therefore, it seems necessary to identify new molecules as anticancer agents. In this process, we synthesized a series of new pyridazin-3(2H)-one derivatives and evaluated their antitumor potential. These cyclic molecules were synthesized and designed as a combination of benzofuran with pyridazinones. All final compounds have been characterized by spectral and elemental analyses to confirm successful synthesis reactions. To evaluate their anticancer activity, all derivatives were assessed against the human breast adenocarcinoma cell line (MCF-7) and the murine mastocytoma cell line (P815) using the methyl tetrazolium Test (MTT assay). The cytotoxic activity was found to be dose-dependent and the IC50 values of the synthesized compounds ranged from 14.5 to 40 μM against MCF-7 and from 35 to 82.5 μM against P815. At the same time, no cytotoxic activity was observed against normal cells. In order to investigate the molecular mechanism of the most cytotoxic product (6f), apoptosis induction was measured against MCF-7 cells. Using the annexin-V FITC staining technique, we showed that the cytotoxic effect of this product is associated with apoptosis induction.